Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

CryoCath: Pulmonary vein isolation ablation with CryoCath's Arctic Front cryoballoon or Arctic Front plus the Freezor Max catheter resulted in maintenance of sinus rhythm in 74% of patients with paroxysmal atrial fibrillation (AF) and 42% of patients with persistent AF in a 346-patient trial led by Thomas Neumann, Kerckhoff Heart Center, Bad Nauheim, Germany. Treatment was considered successful if the patients were AF-free and off anti-arrhythmic drugs one year after a single procedure with the Arctic Front. The results appear in the July 22 Journal of the American College of Cardiology. CryoCath recently completed enrollment in the STOP AF pivotal U.S. trial for Arctic Front and expects FDA approval in late 2009. The device is already available in Europe (1"The Gray Sheet" March 31, 2008, In Brief)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT026447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel